The short version of mass confirmation fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-03-27. Anything still debated is marked as such rather than presented as settled.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
Full-length thymosin beta-4 consists of roughly forty-three amino acids and ranks among the more abundant small proteins in the cytoplasm. The fragment is much shorter, so it cannot reproduce every function attributed to the intact molecule. In cell culture, short actin-binding motifs can interfere with filament dynamics and cell movement, but such observations come from controlled experiments rather than from whole-animal work. Whether a truncated fragment produces the same effects as the parent protein remains an open question.
Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.
| Property | Value | Notes |
|---|---|---|
| Name type | Commercial trade name | Not a systematic chemical identifier |
| Parent peptide | Thymosin beta-4 | 43-residue natural peptide |
| Common fragment sequence | LKKTETQ | Maps to part of the actin-binding region |
| Molecular size class | Roughly 0.8-1.0 kDa | Depends on exact fragment and terminal modification |
| Regulatory status | Prohibited in sport | Grouped with peptide hormones in many frameworks |
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography together with mass spectrometry. The chromatogram provides a purity estimate as a percentage of total peak area, while the mass spectrum confirms that the observed mass matches the expected value. Amino acid analysis or tandem mass spectrometry sequencing can provide additional confirmation. Reported purity figures depend on the column, gradient, and detection wavelength, so values from different laboratories are not directly comparable without method details.
Lyophilised peptide is normally reconstituted with sterile water or a neutral buffer shortly before use. Because repeated freeze-thaw cycles can degrade the material, dividing a reconstituted solution into single-use aliquots is a common practice. Working solutions are usually kept cold and protected from light. The exact shelf life depends on concentration, buffer composition, and handling, so it is often determined empirically rather than assumed.
Peptide bonds are susceptible to hydrolysis under extreme pH and to enzymatic cleavage if proteases are present. Heat, oxidising agents, and prolonged exposure to light also contribute to loss of material. Aggregation can occur at high concentrations or in certain buffer systems, and it may not be visible to the eye. Storage at -20 C or below is typical for both powder and aliquoted solutions, and desiccation of the powder is preferred.
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
Similarly, two molecules that differ only in the isotopes of their atoms (isotopologues) have identical electronic structures, and therefore almost indistinguishable physical and chemical properties (again with deuterium and tritium being the primary exceptions). The vibrational modes of a molecule are determined by its shape and by the masses of its constituent atoms; so different isotopologues have different sets of vibrational modes. Because vibrational modes allow a molecule to absorb photons of corresponding energies, isotopologues have different optical properties in the infrared range.
Nicergoline is an ergot alkaloid derivative that acts as a potent and selective α1A-adrenergic receptor antagonist. The IC50 of nicergoline in vitro has been reported to be 0.2 nM. The primary action of nicergoline is to increase arterial blood flow by vasodilation. Furthermore, it is known that nicergoline inhibits platelet aggregation. Studies have shown that nicergoline also increases nerve growth factor in the aged brain. In addition to the α1A-adrenergic receptor, nicergoline is an antagonist of the serotonin 5-HT1A receptor (IC50 = 6 nM) and shows moderate affinity for serotonin 5-HT2 and α2-adrenergic receptors and low affinity for the dopamine D1 and D2 and muscarinic acetylcholine M1 and M2 receptors.
=== Novo Nordisk === Thomsen joined Novo Nordisk in 1991 as the head of growth hormone research. In 1994, he was appointed senior vice president of diabetes research & development. In November 2000, he became executive vice president and chief scientific officer, overseeing global operations related to drug and device research, chemistry, manufacturing and controls (CMC), global development, medical affairs, regulatory affairs, and safety. During his tenure, more than 20 pharmaceutical products were developed and approved.
== Sports == Russian Paralympic Committee RPC, the IPC code used for Russian Olympic Committee athletes: Russian Paralympic Committee athletes at the 2020 Summer Paralympics Russian Paralympic Committee athletes at the 2022 Winter Paralympics
Sources: en.wikipedia.org
The collected fractions are often examined by spectroscopic techniques to determine the concentration of the particles eluted. Common spectroscopy detection techniques are refractive index (RI) and ultraviolet (UV). When eluting spectroscopically similar species (such as during biological purification), other techniques may be necessary to identify the contents of each fraction. It is also possible to analyze the eluent flow continuously with RI, LALLS, Multi-Angle Laser Light Scattering MALS, UV, and/or viscosity measurements. The elution volume (Ve) decreases roughly linear with the logarithm of the molecular hydrodynamic volume. Columns are often calibrated using 4–5 standard samples (e.g., folded proteins of known molecular weight), and a sample containing a very large molecule such as thyroglobulin to determine the void volume. (Blue dextran is not recommended for Vo determination because it is heterogeneous and may give variable results) The elution volumes of the standards are divided by the elution volume of the thyroglobulin (Ve/Vo) and plotted against the log of the standards' molecular weights.
Skates, rays, small sharks of the genus Mustelus, mullets and bonito were among the fish caught off the Peruvian coast. Other sea creatures like seabirds, penguins, sea lions and dolphins were eaten, as were various crustaceans and chitons, limpets, mussels, chanque (an abalone-like animal). Like other American peoples, the Inca ate animals that were often considered vermin by many Europeans, such as frogs, caterpillars, beetles, and ants. Mayfly larvae were eaten raw or toasted and ground to make loaves that could then be stored. The Inca's intricate food preservation methods and storage system allowed for there to be enough food in times of need (when crops failed, during times of war) or in times of success (when celebrating and rewarding everyone's hard work).
The measurement of molar mass by vapour density relies on the principle, first enunciated by Amedeo Avogadro, that equal volumes of gases under identical conditions contain equal numbers of particles. This principle is included in the ideal gas equation:
Later, Osborn and Weber pioneered fluorescent antibody staining of cellular substructures, a major technique called indirect immunofluorescence microscopy. In developing the method, they tagged microtubules with specific antibodies, then used fluorescently-tagged secondary antibodies (antibodies to the first set of antibodies) to light up the locations of the microtubules in cells. When they began their work in Germany, the cytoskeleton was not heavily researched. Microtubules and microfilaments were known, and they established that microtubules always reacted with antibodies to tubulins while microfilaments always reacted with antibodies to actin. In the course of their studies, they also found intermediate filaments, slightly thicker than microfilaments, and unreactive to actin antibodies. They developed new antibodies against proteins of the microtubules, intermediate filaments, and microfilaments to use as reagents in examining many types of cells. Many of their antibodies have been licensed to companies for commercial development. Klaus and Osborn used their method to study elements of the cytoskeleton of eukaryotic cells in two dimensions and three dimensions. Osborn has extensively studied microtubules, intermediate filaments, microfilaments, and nuclear proteins as well as other proteins that can associate with these structures. By 1981 Osborn and Klaus had shown conclusively intermediate filaments in different types of cells are different but related, and they can be distinguished using immunofluorescence.
The mendelevium separated by this method has the advantage of being free of organic complexing agent compared to the resin column; the disadvantage is that mendelevium then elutes very late in the elution sequence, after fermium. Another method to isolate mendelevium exploits the distinct elution properties of Md2+ from those of Es3+ and Fm3+. The initial steps are the same as above, and employs HDEHP for extraction chromatography, but coprecipitates the mendelevium with terbium fluoride instead of lanthanum fluoride. Then, 50 mg of chromium is added to the mendelevium to reduce it to the +2 state in 0.1 M hydrochloric acid with zinc or mercury. The solvent extraction then proceeds, and while the trivalent and tetravalent lanthanides and actinides remain on the column, mendelevium(II) does not and stays in the hydrochloric acid. It is then reoxidized to the +3 state using hydrogen peroxide and then isolated by selective elution with 2 M hydrochloric acid (to remove impurities, including chromium) and finally 6 M hydrochloric acid (to remove the mendelevium). It is also possible to use a column of cationite and zinc amalgam, using 1 M hydrochloric acid as an eluant, to effect the reduction. Thermochromatographic chemical isolation could be achieved using the volatile mendelevium hexafluoroacetylacetonate: the analogous fermium compound is known and similar.
Sources: en.wikipedia.org
No. Thymosin beta-4 is a 43-residue natural peptide, while TB-500 is a commercial label applied to a short synthetic fragment of it. The two differ in length, sequence coverage and how they are handled in the laboratory.
Published work usually examines actin binding, cell migration and tissue repair endpoints in cell and animal models. Findings are generally described as preliminary, and controlled human data remain limited.
Because TB-500 is a trade name rather than a chemical identifier, different vendors and papers may attach it to different fragment lengths. Checking the stated sequence is the practical way to resolve the ambiguity.
It is a synthetic peptide based on a short sequence near the start of thymosin beta-4. It is supplied as a research chemical rather than as a licensed pharmaceutical product.